Alto Neuroscience, Inc. ANRO 深 滬
交易中 09-20 13:25:09 美东时间
13.11
-0.320
-2.38%
華盛通- 最 高13.535
- 今 開13.20
- 成交量 20.26万股
- 最 低 12.80
- 昨 收 13.43
- 總市值 3.51亿
- 52周最高 24.00
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 7.91
- 委 比 52.67%
- 總股本 2678.04万
- 歷史最高 24.00
- 量 比 1.13
- 振 幅 5.47%
- 歷史最低 7.91
- 每 手 1
- 風險率 2.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wedbush Reiterates Outperform on Alto Neuroscience, Maintains $29 Price Target
Wedbush analyst Laura Chico reiterates Alto Neuroscience (NYSE:ANRO) with a Outperform and maintains $29 price target.
09-10 20:52
Alto Neuroscience Completes Enrollment In ALTO-100 Phase 2b Study, Topline Results Expected In October
300 patients enrolled in the study, including patients with and without the cognitive biomarker – On track to report topline data in October 2024 – Alto to host investor day focused on ALTO-100 on
07-16 19:36
Alto Neuroscience appoints Michael Hanley as COO
Alto Neuroscience (NYSE:ANRO) said it has appointed industry veteran Michael Hanley as chief operating officer. Hanley has over 25 years of leadership experience in the life sciences industry, and mos...
05-21 20:21
Alto Neuroscience Q1 2024 Adj EPS $(0.76) Misses $(0.46) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.46) by 65.22 percent.
05-15 04:23
Alto Neuroscience schizophrenia treatment shows good phase 1 results
ALTO-101, a novel PDE4 inhibitor under investigation from Alto Neuroscience (NYSE:ANRO) for cognitive impairment associated with schizophrenia ("CIAS"), demonstrated positive phase 1 results in health...
04-24 01:21
Stifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy ...
03-25 19:45
Buy Rating Affirmed: Alto Neuroscience’s Promising Clinical Trials Signal Market Potential
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Alto Neuroscie...
03-25 09:47
Alto Neuroscience GAAP EPS of -$9.73
Alto Neuroscience press release (NYSE:ANRO): FY GAAP EPS of -$9.73. As of December 31, 2023, Alto had cash and cash equivalents of $82.5 million. The Company expects its cash balance to support planne...
03-22 04:49
细胞治疗公司Kyverna纳斯达克上市：上涨36% 市值12亿美元，路演PPT曝光
Kyverna发行价为22美元，大幅高于此前的发行区间17美元到19美元；此次发行1450万股，募资总额为3.19亿美元。
02-12 15:33
今年美股药企第二大IPO来了！Kyverna(KYTX.US)今晚上市 筹资3.19亿美元
© Reuters. 今年美股药企第二大IPO来了！Kyverna(KYTX.US)今晚上市 筹资3.19亿美元 KYM...
02-08 14:36
